The dysregulation of GALNT2 contributes to the malignant behavior of hepatocellular carcinoma cells, and enhances the motility of oral squamous cell carcinoma [23, 24], whereas GALNT2 has also been reported to suppress malignant phenotypes in neuroblastoma and gastric adenocarcinoma [25, 26]. This evidence concerns the gene GALNT2 and neuroblastoma.